GlassScriptPhysician profile
Rebecca D Lashbrook
NPI 1053305219
$4,886.34
in general payments reported to CMS, 2019-2025
35 companies · $785 in 2025
The $785 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $304 · 2021: $850 · 2022: $847 · 2023: $731 · 2024: $840 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,326.25 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,083.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $719.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $412.58 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.86 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $358.43 | 2019-2025 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $357.03 | 2019-2025 | Gardasil 9, Vaxelis, Rotateq |
| Abbvie INC. | $258.85 | 2021-2024 | |
| Pfizer INC. | $214.86 | 2019-2024 | |
| Currax Pharmaceuticals LLC | $157.26 | 2020-2025 | Onzetra Xsail, Contrave, Nexletol |
| Glaxosmithkline, LLC. | $155.34 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $91.93 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $71.72 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.30 | 2019-2022 | |
| Boston Scientific Corporation | $51.95 | 2022-2025 | Watchman Flx, Versacross Access Solution |
| Teva Pharmaceuticals USA, INC. | $50.00 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $44.09 | 2020-2022 | |
| Allergan, INC. | $43.48 | 2019 | |
| Abbott Laboratories | $38.81 | 2022-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $38.31 | 2021 | |
| Sanofi Pasteur INC. | $30.76 | 2024 | |
| Janssen Pharmaceuticals, INC | $27.13 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $25.32 | 2019 | |
| Mayne Pharma Commercial LLC | $22.94 | 2022 | |
| Amneal Pharmaceuticals LLC | $21.00 | 2023 | Unithroid |
| Esperion Therapeutics, INC. | $19.41 | 2020 | |
| Shire North American Group INC | $18.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.53 | 2023 | |
| Viatris Specialty LLC | $16.51 | 2025 | Yupelri |
| Daiichi Sankyo INC. | $16.13 | 2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.44 | 2025 | Xifaxan |
| Acadia Pharmaceuticals INC | $15.17 | 2025 | Nuplazid |
| Dexcom, INC. | $15.09 | 2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $14.97 | 2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $14.28 | 2023 | Keveyis |
| Celgene Corporation | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Lashbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.